Johnson & Johnson (NYSE: JNJ) will pay $2 billion in cash to acquire Ambrx Biopharma Inc. (Nasdaq: AMAM), gaining a developer of widely sought drugs that target tumors with lethal drugs.
To read the entire story, you must be logged in.
Please log in now or register with us.
